Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nikhil Bassi

Cardiovascular Disease Newport Beach, CA Medical Doctor

NPI 1679911457 CMS profile 781143

520 Superior Ave Ste 325, Newport Beach, CA 92663

Open in the dashboard

General payments

$19,854

776 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nikhil Bassi of Newport Beach, CA is reported in the CMS Open Payments database as having received $19,854 across 776 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,438 125
2024 General $3,777 127
2023 General $4,284 154
2022 General $3,150 151
2021 General $3,075 163
2020 General $1,002 54
2019 General $129 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nikhil Bassi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Nikhil Bassi were reported at $4,438. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Nikhil Bassi Cardiovascular Disease median Middle half National median
2019 $129 $450 $127–$1,392 $163
2020 $1,002 $242 $77–$751 $114
2021 $3,075 $335 $101–$1,037 $132
2022 $3,150 $395 $121–$1,211 $149
2023 $4,284 $443 $136–$1,283 $160
2024 $3,777 $450 $136–$1,323 $164
2025 $4,438 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $3,475 6 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,473 70 payments
  3. Amgen Inc. $1,448 66 payments
  4. Novartis Pharmaceuticals Corporation $1,437 76 payments
  5. Pfizer Inc. $1,223 68 payments
  6. Alnylam Pharmaceuticals Inc. $1,059 50 payments
  7. E.R. Squibb & Sons, L.L.C. $849 49 payments
  8. AstraZeneca Pharmaceuticals LP $754 42 payments
  9. Novo Nordisk Inc $637 28 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $623 30 payments
  11. Other $6,877 291 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,375 770 payments
  2. Consulting Fee $3,400 3 payments
  3. Education $65 2 payments
  4. Entertainment $15 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $1,355 61 payments
  2. VYNDAQEL $978 54 payments
  3. JARDIANCE Diabetes $770 35 payments
  4. LEQVIO $768 41 payments
  5. JARDIANCE Diabetes $691 34 payments
  6. AMVUTTRA $653 30 payments
  7. LifeVest $623 30 payments
  8. FARXIGA $609 34 payments
  9. Vascepa $602 30 payments
  10. XARELTO $555 27 payments
  11. Other $10,415 474 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

3,270

Median for Cardiology: 2,533

Drug cost

$1,924,668

Median for Cardiology: $485,213

Branded share of claims

34.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 14 $912,818
Eliquis Apixaban Brand 381 $445,785
Repatha Sureclick Evolocumab Brand 146 $170,875
Entresto Sacubitril/Valsartan Brand 134 $146,618
Jardiance Empagliflozin Brand 75 $86,249
Xarelto Rivaroxaban Brand 50 $64,646
Farxiga Dapagliflozin Propanediol Brand 35 $31,094
Nebivolol Hcl Generic 155 $11,894
Brilinta Ticagrelor Brand 15 $11,803
Rosuvastatin Calcium Generic 368 $6,566

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$412,790

Of which drugs: $161,807

Medicare patients

707

Average age 77

Services billed

21,118

361 women, 346 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 43%
Cancer 29%
Atrial fibrillation 28%
Diabetes 26%
Chronic kidney disease 25%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 33 17,892 $161,563
Infusion, normal saline solution, 250 cc J7050 Office 17 68 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $281
$281 75 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $208
$208 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $195
$195 — 17,892
VYNDAQEL
  • PFIZER INC. $142
$142 — —
Repatha
  • Amgen Inc. $134
$134 146 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

776 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record